Hepatitis C Virus

December 3, 2024 Research Highlights

Cost-Effectiveness of Fibrosis Staging

More than 4 million people in the U.S. live with a hepatitis C virus (HCV) diagnosis. However, as of 2022, fewer than one-third of individuals infected with HCV have been cured due to barriers related to high direct-acting antiviral (DAA) pricing and the steps involved in determining someone’s degree of liver disease or fibrosis. In […]

November 6, 2024 Research Highlights

Racial and Ethnic Disparities Along the Hepatitis C Care Cascade Among Priority Populations

Over the last two decades, injection opioid use has increased among reproductive-aged women, with resultant increases in mother-to-child hepatitis C virus (HCV) transmissions in the U.S. Direct-acting antiviral (DAA) treatment is highly effective at reducing and eliminating the risk of HCV transmissions. Yet, studies show lower odds of receiving DAA treatment for women compared to […]

October 16, 2024 Profile Feature

Announcing the 10th Pilot Grant Cohort Advancing the Treatment of Substance Use Disorders, HCV, and HIV

CHERISH is excited to welcome a new pilot grant cohort for the 10th year. Spearheaded by CHERISH Pilot Grant Program Director Brandon Aden, the program is designed to help researchers gain familiarity with health economic evaluations, apply related methodologies to their pilot research, and build out the next stage of their careers. This year, CHERISH […]

August 12, 2024 Research Highlights

Association between claims-based setting of diagnosis and treatment initiation among Medicare patients with Hepatitis C

Direct-acting antivirals (DAAs) have been available since 2015 for hepatitis C (HCV). Nonetheless, very few patients with HCV initiate DAA treatment, ranging from 5% to 30%. The location where a patient is first diagnosed can also influence the care patients receive afterward, especially when a referral to a specialist or coordinated care is needed. In […]

May 2, 2024 Research Highlights

Cost-Effectiveness of Strategies for Treatment Timing for Perinatally Acquired Hepatitis C Virus

Children with perinatally acquired hepatitis C virus (HCV) are now eligible to receive direct-acting antivirals (DAAs), a highly effective treatment for HCV, as early as the age of 3. Despite existing studies demonstrating DAA’s high efficacy and tolerance among adults and children between the 3 and 12 years old, there has been low uptake due […]

Engage with CHERISH

Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.